Exosomal microRNAs: Pleiotropic Impacts on Breast Cancer Metastasis and Their Clinical Perspectives

Tang, Libo; Ma, Shu-Xin; Chen, Zhuohui; Huang, Qi-Yuan; Wu, Longyuan; Wang, Yi; Zhao, Ruichen; Xiong, Likuan

doi:10.3390/biology10040307

Cited by 9 publications

(6 citation statements)

References 182 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, the potential of exomiRs is being assessed as a novel therapy strategy of cancer and other diseases [ 171 , 172 , 173 ]. In BC, c-miRNAs and exomiRs have been shown to affect essential features such as tumor growth, invasion and angiogenesis [ 174 ]. For example, the circulating exosomal miRNAs miR-92 and miR-25-3p in BC patients can induce angiogenesis and epithelial–mesenchymal transition (EMT).…”

Section: Non-coding Rnasmentioning

confidence: 99%

Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer

Treeck¹,

Ortmann²

2023

Cancers

View full text Add to dashboard Cite

The largest part of human DNA is transcribed into RNA that does not code for proteins. These non-coding RNAs (ncRNAs) are key regulators of protein-coding gene expression and have been shown to play important roles in health, disease and therapy response. Today, endocrine therapy of ERα-positive breast cancer (BC) is a successful treatment approach, but resistance to this therapy is a major clinical problem. Therefore, a deeper understanding of resistance mechanisms is important to overcome this resistance. An increasing amount of evidence demonstrate that ncRNAs affect the response to endocrine therapy. Thus, ncRNAs are considered versatile biomarkers to predict or monitor therapy response. In this review article, we intend to give a summary and update on the effects of microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) on estrogen signaling in BC cells, this pathway being the target of endocrine therapy, and their role in therapy resistance. For this purpose, we reviewed articles on these topics listed in the PubMed database. Finally, we provide an assessment regarding the clinical use of these ncRNA types, particularly their circulating forms, as predictive BC biomarkers and their potential role as therapy targets to overcome endocrine resistance.

show abstract

Section: Non-coding Rnasmentioning

confidence: 99%

Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer

Treeck¹,

Ortmann²

2023

Cancers

View full text Add to dashboard Cite

show abstract

“…There is a need to understand the molecular mechanism in chemoresistance to minimize the recurrence rate. Many studies showed the role of exosomal miRNA in the induction of chemoresistance in breast cancer ( Tang et al, 2021 ). Here, we review some signaling pathways that are specifically targeted by exosomal miRNA to regulate the particular drug sensitivity of breast cancer (see Table 1 ).…”

Section: Exosomal Micrornas In Bc For Chemoresistancementioning

confidence: 99%

Exosomal miRNAs as novel avenues for breast cancer treatment

et al. 2023

View full text Add to dashboard Cite

Breast cancer is the most commonly diagnosed cancer and a leading cause of death in women worldwide. It is a heterogeneous disease, as shown by the gene expression profiles of breast cancer samples. It begins in milk-producing ducts, with a high degree of diversity between and within tumors, as well as among cancer-bearing individuals. The enhanced prevalence of breast cancer is influenced by various hormonal, lifestyle, and environmental factors, and very early onset of the disease correlates strongly with the risk of local and distant recurrence. Many subtypes are difficult to treat with conventional therapeutic modalities, and therefore, optimal management and early diagnosis are the first steps to minimizing the mortality linked with breast cancer. The use of newer methods of nanotechnology extends beyond the concept of synthesizing drug delivery mechanisms into the creation of new therapeutics, such as delivering chemotherapeutics with nanomaterial properties. Exosomes, a class of nanovesicles, are emerging as novel tools for deciphering the patient-specific proteins and biomarkers across different disease models, including breast cancer. In this review, we address the role of exosomal miRNA in breast cancer diagnosis and treatment.

show abstract

“…Another class of potential biomarkers present in circulation are small noncoding microRNAs (miRNAs), which play roles in the regulation of gene expression [ 118 ]. miRNAs secreted from exosomes improved the migration capacity of several BC cell lines [ 119 , 120 ]. miR-105, miR-122, and miR-106b are characteristically expressed and secreted by metastatic BC cells, promoting invasion and metastasization [ 110 , 121 ].…”

Section: Hsp27 Hsp60 Hsp70 and Hsp90 In Bc Therapeutics: Negative Cha...mentioning

confidence: 99%

The Chaperone System in Breast Cancer: Roles and Therapeutic Prospects of the Molecular Chaperones Hsp27, Hsp60, Hsp70, and Hsp90

Alberti

Vergilio

Paladino

et al. 2022

IJMS

View full text Add to dashboard Cite

Breast cancer (BC) is a major public health problem, with key pieces of information needed for developing preventive and curative measures still missing. For example, the participation of the chaperone system (CS) in carcinogenesis and anti-cancer responses is poorly understood, although it can be predicted to be a crucial factor in these mechanisms. The chief components of the CS are the molecular chaperones, and here we discuss four of them, Hsp27, Hsp60, Hsp70, and Hsp90, focusing on their pro-carcinogenic roles in BC and potential for developing anti-BC therapies. These chaperones can be targets of negative chaperonotherapy, namely the elimination/blocking/inhibition of the chaperone(s) functioning in favor of BC, using, for instance, Hsp inhibitors. The chaperones can also be employed in immunotherapy against BC as adjuvants, together with BC antigens. Extracellular vesicles (EVs) in BC diagnosis and management are also briefly discussed, considering their potential as easily accessible carriers of biomarkers and as shippers of anti-cancer agents amenable to manipulation and controlled delivery. The data surveyed from many laboratories reveal that, to enhance the understanding of the role of the CS in BS pathogenesis, one must consider the CS as a physiological system, encompassing diverse members throughout the body and interacting with the ubiquitin–proteasome system, the chaperone-mediated autophagy machinery, and the immune system (IS). An integrated view of the CS, including its functional partners and considering its highly dynamic nature with EVs transporting CS components to reach all the cell compartments in which they are needed, opens as yet unexplored pathways leading to carcinogenesis that are amenable to interference by anti-cancer treatments centered on CS components, such as the molecular chaperones.

show abstract

Exosomal microRNAs: Pleiotropic Impacts on Breast Cancer Metastasis and Their Clinical Perspectives

Cited by 9 publications

References 182 publications

Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer

Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer

Exosomal miRNAs as novel avenues for breast cancer treatment

The Chaperone System in Breast Cancer: Roles and Therapeutic Prospects of the Molecular Chaperones Hsp27, Hsp60, Hsp70, and Hsp90

Contact Info

Product

Resources

About